AJ

Abdul Jameel

Active Director Director DIN 11076627
DIN 11076627 First appointment Apr 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Abdul Jameel

Data last updated:

Abdul Jameel is a Director at Zar Eaglon Pharmaceuticals Private Limited (since 2025). The company operates in Pharma.

DIN 11076627
Primary Designation Director
Industry Pharma
First Appointment 25 Apr 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director25 Apr 20252025Active

Board colleagues of Abdul Jameel

Directorship timeline

Open interactive timeline →
Zar Eaglon Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Abdul Jameel

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Abdul Jameel

Abdul Jameel currently holds 1 directorship: Zar Eaglon Pharmaceuticals Private Limited (Director, since 25 Apr 2025).

Abdul Jameel was first appointed on 25 Apr 2025 as Director at Zar Eaglon Pharmaceuticals Private Limited.

The current boards of Abdul Jameel's companies include Mohd Zulfeqar Hashim Khan (Zar Eaglon Pharmaceuticals Private Limited), Safia Sheerin (Zar Eaglon Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available